# Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

> **NCT05481645** · PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 71 (actual)

## Conditions studied

- Advanced Endometrial Cancer
- Sarcoma of Uterus

## Interventions

- **DRUG:** TQB2450 injection
- **DRUG:** Anlotinib Hydrochloride Capsule
- **DRUG:** Carboplatin Injection
- **DRUG:** Paclitaxel Injection
- **DRUG:** Doxorubicin Hydrochloride Injection
- **DRUG:** Gemcitabine Hydrochloride Injection
- **DRUG:** Docetaxel injection

## Key facts

- **NCT ID:** NCT05481645
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-26
- **Primary completion:** 2024-02-01
- **Final completion:** 2025-11-30
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05481645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05481645, "Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05481645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*